Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2005)
16 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2005
Slide 1: Fisher & Paykel Healthcare
Fisher Payk HEALTHC
Slide 2: Consistent Growth Strategy
Consistent Growth Strategy • Innovative devices which improve care and outcomes • Increase value per patient • New patient groups • International expansion 1
Slide 3: Financial Highlights
Financial Highlights • Operating revenue US$163M +23% NZ$241M +12% • Operating profit US$61M +25% NZ$90M +14% • Operating margin 37.3% • R&D investment increased to 6.7% of revenue 2
Slide 4: Sales by Product Group
Sales by Product Group Distributed 3% Respiratory Warming & Humidification Neonatal 49% 8% OSA 40% 3
Slide 5: Sales by Region
Sales by Region Asia Pacific Other 21% 5% North America Europe 43% 31% 4
Slide 6: Expanding International Presence
Expanding International Presence 5
Slide 7: Obstructive Sleep Apnea
Obstructive Sleep Apnea Fisher & Paykel HAEALTHCARE
Slide 8: Obstructive Sleep Apnea
Obstructive Sleep Apnea • Revenue grew 34% to US$66M • Masks and flow generators grew 70% • OSA treatment market continues to expand rapidly 15-20% p.a. 7
Slide 9: New Flow Generators & Masks
New Flow Generators & Masks • Introduced new flow generator ranges SleepStyle™ 200 and 600 series • ThermoSmart technology to increase humidity, improve comfort and acceptance • New masks well received FlexiFit™ 431 Infinity™ 481 Full Face Mask Direct Nasal Mask 8
Slide 10: Respiratory Humidification
Respiratory Humidification 9
Slide 11: Respiratory Humidification
Respiratory Humidification • Revenue growth • Increasing value per 16% to US $79M patient • Continuing rapid • Evaqua breathing growth of breathing circuit technology circuits well received 10
Slide 12: Expanding Opportunities
Expanding Opportunities • MR880 Humidification System – Designed for a range of new patient groups, e.g. O2 therapy, COPD, xerostomia. • MR860 Laparoscopic Humidification System – Humidifies the dry CO2 gas used in ‘keyhole’ surgery. – Improves outcomes by: less post operative pain, less time in rec
Slide 13: Neonatal
Neonatal • Revenue growth 31% to US$13M • Warmers, neonatal breathing systems grew strongly • Increasing proportion of recurring revenue 12
Slide 14: Capacity Expansion
Capacity Expansion • NZ$60M investment to • On target for accommodate growth completion mid-2006 13
Slide 15: First Half Outlook
First Half Outlook • USD Revenue growth approx 25% – US$ 93 – 95M – NZ$ 132 – 135M • Operating Margin % mid 30s 14
Slide 16: Fisher & Paykel Healthcare
FishersPa HEALTHC
Fisher & Paykel Healthcare — Shareholder Meeting (2005) on 6ix